Targeted therapy of glioblastoma stem-like cells and tumor non-stem cells using cetuximab-conjugated iron-oxide nanoparticles

Citations Over TimeTop 10% of 2015 papers

Abstract

Malignant gliomas remain aggressive and lethal primary brain tumors in adults. The epidermal growth factor receptor (EGFR) is frequently overexpressed in the most common malignant glioma, glioblastoma (GBM), and represents an important therapeutic target. GBM stem-like cells (GSCs) present in tumors are felt to be highly tumorigenic and responsible for tumor recurrence. Multifunctional magnetic iron-oxide nanoparticles (IONPs) can be directly imaged by magnetic resonance imaging (MRI) and designed to therapeutically target cancer cells. The targeting effects of IONPs conjugated to the EGFR inhibitor, cetuximab (cetuximab-IONPs), were determined with EGFR- and EGFRvIII-expressing human GBM neurospheres and GSCs. Transmission electron microscopy revealed cetuximab-IONP GBM cell binding and internalization. Fluorescence microscopy and Prussian blue staining showed increased uptake of cetuximab-IONPs by EGFR- as well as EGFRvIII-expressing GSCs and neurospheres in comparison to cetuximab or free IONPs. Treatment with cetuximab-IONPs resulted in a significant antitumor effect that was greater than with cetuximab alone due to more efficient, CD133-independent cellular targeting and uptake, EGFR signaling alterations, EGFR internalization, and apoptosis induction in EGFR-expressing GSCs and neurospheres. A significant increase in survival was found after cetuximab-IONP convection-enhanced delivery treatment of 3 intracranial rodent GBM models employing human EGFR-expressing GBM xenografts.

Related Papers

• → Lack of usefulness of epidermal growth factor receptor expression determination for cetuximab therapy in patients with colorectal cancer(2006)110 cited
• → Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab(2016)44 cited
• → Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII(2007)35 cited
• → Recent results of cetuximab use in the treatment of squamous cell carcinoma of the head and neck(2009)5 cited
• → Abstract 836: ISU104, a fully human anti-ErbB3 antibody, overcomes acquired cetuximab resistance(2018)2 cited